Sistek D, Kelly R, Wickens K, Stanley T, Fitzharris P, Crane J
Wellington Asthma Research Group, Department of Medicine, School of Medicine and Health Sciences, Wellington, New Zealand.
Clin Exp Allergy. 2006 May;36(5):629-33. doi: 10.1111/j.1365-2222.2006.02485.x.
Probiotics have previously been shown to reduce the severity of atopic dermatitis (AD) in infants and children.
To examine the effect of two probiotics (Lactobacillus rhamnosus and Bifidobacteria lactis) on established AD in children.
Atopic children with current dermatitis received 2 x 10(10) colony forming units/g of probiotic (n=29) or placebo (n=30). Both were given daily as a powder mixed with food or water. SCORing Atopic Dermatitis (SCORAD; developed by the European Task Force on Atopic Dermatitis) a measure of the extent and severity of AD, was assessed at baseline, 2 and 12 weeks after starting treatment and 4 weeks after treatment was discontinued.
SCORAD geometric mean score at baseline was 26.0 (21.9-30.8) in the probiotic group and 35.1 (28.9-42.8) in the placebo group (P=0.02). After adjustment for these between-group baseline differences there was no significant improvement in AD at 12 weeks, SCORAD geometric mean ratio: 0.80 (95% confidence level (CI) 0.62-1.04, P=0.10). Among the food sensitized children, there was an improvement in those treated with probiotics, SCORAD geometric mean ratio: 0.73 (95% CI 0.54-1.00, P=0.047).
In this study a combination of Lactobacillus rhamnosus and Bifidobacteria lactis improved AD only in food sensitized children.
先前的研究表明，益生菌可减轻婴幼儿特应性皮炎（AD）的严重程度。
研究两种益生菌（鼠李糖乳杆菌和乳酸双歧杆菌）对儿童已患AD的影响。
患有当前性皮炎的特应性儿童接受2×10¹⁰菌落形成单位/克的益生菌（n = 29）或安慰剂（n = 30）。两者均每日以粉末形式与食物或水混合服用。采用特应性皮炎评分（SCORAD；由欧洲特应性皮炎工作组制定）来衡量AD的范围和严重程度，在基线、开始治疗后2周和12周以及治疗停止后4周进行评估。
益生菌组基线时SCORAD几何平均评分为26.0（21.9 - 30.8），安慰剂组为35.1（28.9 - 42.8）（P = 0.02）。在对组间基线差异进行调整后，12周时AD无显著改善，SCORAD几何平均比值：0.80（95%置信区间（CI）0.62 - 1.04，P = 0.10）。在食物过敏的儿童中，接受益生菌治疗的儿童病情有所改善，SCORAD几何平均比值：0.73（95% CI 0.54 - 1.00，P = 0.047）。
在本研究中，鼠李糖乳杆菌和乳酸双歧杆菌的组合仅在食物过敏的儿童中改善了AD。
